Replies to post #185080 on Amarin Corp Plc (AMRN)

[ranjo]

co promote is the only way amrn keeps a big slice of the pie for themselves. the co promote needs to be a win win .. amrn will need to give up some profits early on to get to the hockey stick pattern quicker. this is done frequently, exas, is a great example watch Q1 #s compared to YoY 2018. pfe came on board essentially in October 2018

[chas1232123]

I don’t know what peak V sales will be, but I believe they will be shockingly high, before terribly long. Already sharply accelerating, the big move will be after label expansion IMO, which I expect to be expedited. Three digits within 3 years.

[Markipeach]

Baloney. I was a Mfg Rep for 20 years selling multiple lines. I always led in with my top product. PFE reps would sell the H—- out of V

[couldbebetter]

raistthemage, Any company acquiring AMRN would have Vascepa sold
by reps who have contact with Cardiologists and Endocrinologists.
Most reps have regular contact with their doctor clientele. Because
Vascepa has 10 years left before generic competition the earliest
adopters of Vascepa are the most valuable as those will provide 9
years of scripts from the first year, 8 years of scripts from the
second year, and so on. This would mean that the company would
provide incentives to assure their sales goals are achieved.

Perhaps JT will decide to GIA and make AMRN into its own BP.
If we past 2019 without a public bid then I'd say the odds of
of buyout would be much lower. However, given the synergies
that BP would provide (not to mention all of the cash that JT
would walk away with) I would be truly amazed if JT does not
follow that route.